Tuesday, September 26, 2023

561.316.3330

Biotechnology News Magazine

Revolo Biotherapeutics Announces That the Last Patient in its Phase 2a Trial of ‘1104 in Eosinophilic Esophagitis has Completed the Study

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the last patient has completed a Phase 2a proof of concept clinical study investigating its immune-resetting molecule, ‘1104, for the treatment of patients with eosinophilic esophagitis (EoE).

“The last patient out marks a key milestone in our Phase 2a trial in EoE, and we are looking forward to announcing topline data early next year,” said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics. “’1104 has the unique ability to reset the immune system ahead of the inflammatory cascade, providing a potentially promising new treatment option for patients without causing immunosuppression. ‘1104 stands out from other drug products that treat allergic disease by its broad effect in reducing a spectrum of key inflammatory cytokines and reduction of inflammatory immune cells, such as eosinophils, mast cells, neutrophils and lymphocytes. We are confident that the data in early 2023 will support its potential to have an improvement in symptomatic and physiologic response for EoE patients.”

Evan Dellon, M.D., MPH, Gastroenterologist, Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina Chapel Hill, and Principal Investigator for the clinical trial, added, “Despite the approval of the first treatment for EoE patients earlier this year, many are still very much in need of an effective and safe option to treat this complex and life-changing disease. Data from this study will provide insight into the safety and efficacy of ‘1104 in patients with EoE and, if positive, will inform the design of future late-stage studies. In the interest of patients, I am eager to see the data from this novel drug product.”

The Phase 2a, randomized, double-blind, placebo-controlled trial (NCT05084963) is designed to evaluate the safety and efficacy of ‘1104 in adults with EoE. Top line data is expected in early 2023.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine